For patients with unresectable HCC who have not been treated previously, atezolizumab, an anti-PD-L1 mAb, in combination with bevacizumab, an anti-VEGF mAb, was found to have improved OS and PFS compared to sorafenib [22]. Here, CD274 is linked to hepatocellular carcinoma.